Andere Sprachen Natera, Inc.

Aktien

A14VPJ

US6323071042

NTRA

Gesundheitspflege Einrichtungen

Verzögert Nasdaq Andere Börsenplätze 21:54:45 22.01.2025			% 5 Tage	% 1. Jan.
172.10 ^USD	+2.77%		+0.85%	+8.53%

00:05	Natera präsentiert neue Daten auf dem ASCO GI Symposium 2025	CI
15.01.	Natera, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 09:00 AM

Andere Sprachen

Natera to Present New Data at the 2025 ASCO GI Symposium	00:06
Natera to Present New Data at the 2025 ASCO GI Symposium	00:05
Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year	20.01.
Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year	17.01.
Natera : 43rd Annual J.P. Morgan Healthcare Conference	15.01.
Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection	15.01.
Natera Provides Details on Its Innovation Roadmap for Oncology	15.01.
Natera, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2024	13.01.
Natera Says Preliminary Q4 Revenue Up 52%	13.01.
Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024	13.01.
Guardant Health Holds 'Underappreciated' Catalyst Path, UBS Says	10.01.
Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference	07.01.
Momentum Picks 1T 2025: 5 valores para el invierno	02.01.
Momentum Picks Q1 2025: vijf aandelen voor de winter	02.01.
Momentum Picks Q1 2025: 5 titoli per l’inverno	02.01.
Momentum Picks Q1 2025: 5 stocks for winter	02.01.
Momentum Picks T1 2025 : 5 actions pour l'hiver	02.01.
Court Grants Natera's Request to Include Additional Patent in its Lawsuit against NeoGenomics	18.12.
Natera Expands Lawsuit Against NeoGenomics to Include Additional Patent	17.12.
Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics	17.12.
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer	12.12.
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer	12.12.
Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment	09.12.
Natera and MyOme Announce Launch of iPRS for Breast Cancer Risk Assessment	09.12.
Natera Insider Sold Shares Worth $14,793,563, According to a Recent SEC Filing	04.12.

Werden Sie Mitglied, um Zugang zu mehr Nachrichten zu erhalten.

100% kostenlose Registrierung

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Natera, Inc.

Aktien

A14VPJ

US6323071042

NTRA

Gesundheitspflege Einrichtungen

Andere Sprachen

Filter